Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice

Virology Journal

Volumn 10, Issue , 2013, Pages

  Warimwe, George M ^a   Lorenzo, Gema ^b   Lopez Gil, Elena ^b   Reyes Sandoval, Arturo ^a   Cottingham, Matthew G ^a   Spencer, Alexandra J ^a   Collins, Katharine A ^a   Dicks, Matthew Dj ^a   Milicic, Anita ^a   Lall, Amar ^a   Furze, Julie ^a   Turner, Alison V ^a   Hill, Adrian Vs ^a   Brun, Alejandro ^b   Gilbert, Sarah C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

Author keywords

Adenovirus vector; Rift Valley Fever; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; RIFT VALLEY FEVER VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; RIFT VALLEY FEVER; SPLEEN CELL;

ADENOVIRIDAE; CHIMPANZEE ADENOVIRUS; HUMAN ADENOVIRUS TYPE 5; MUS;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; GENETIC VECTORS; MICE; MICE, INBRED BALB C; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84889001254     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-349     Document Type: Article

References (51)

1. ILRI, Mapping of poverty and likely zoonoses hotspots (zoonoses project 4) United Kingdom: Report to Department for International Development 2012 http://www.dfid.gov.uk/r4d/Output/190314/Default.aspx
2. Neglected tropical diseases of the Middle East and North Africa: review of their prevalence, distribution, and opportunities for control. Hotez PJ, Savioli L, Fenwick A, PLoS Negl Trop Dis 2012 6 1475 10.1371/journal.pntd. 0001475 22389729
3. Enzootic Hepatitis or Rift Valley fever: an undescribed virus disease of sheep, cattle and man from East Africa. Daubney R, Hudson JR, Granham PC, J Pathol Bacteriol 1931 34 545 579 10.1002/path.1700340418
4. Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Dungu B, Louw I, Lubisi A, Hunter P, von Teichman BF, Bouloy M, Vaccine 2010 28 4581 4587 10.1016/j.vaccine.2010.04.085 20470792
5. Human infection with Rift Valley fever virus and immunity twelve years after single attack. Sabin AB, Blumberg RW, Proc Soc Exp Biol Med 1947 64 385 389 10.3181/00379727-64-15803 20239431
6. Findlay GM, Ordinary meeting of the Royal Society; December 10 Keppel Street, London: London School of Hygiene and Tropical Medicine Rift valley fever or enzootic hepatitis. 1931
7. Persistence of antibodies to Rift Valley Fever in man. Brown RD, Scott GR, Dalling T, Lancet 1957 270 345
8. Notes on Rift Valley fever. Findlay GM, Howard EM, Arch Gesamte Virusforsch 1951 4 411 423 10.1007/BF01241162 13249478
9. Complete nucleotide sequence of the M RNA segment of Rift Valley fever virus. Collett MS, Purchio AF, Keegan K, Frazier S, Hays W, Anderson DK, Parker MD, Schmaljohn C, Schmidt J, Dalrymple JM, Virology 1985 144 228 245 10.1016/0042-6822(85)90320-4 2998042 (Pubitemid 15226185)
10. Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. Keegan K, Collett MS, J Virol 1986 58 263 270 2422392 (Pubitemid 16013616)
11. Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Schmaljohn CS, Parker MD, Ennis WH, Dalrymple JM, Collett MS, Suzich JA, Schmaljohn AL, Virology 1989 170 184 192 10.1016/0042-6822(89)90365-6 2655274 (Pubitemid 19133974)
12. Novel approaches to develop Rift Valley fever vaccines. Indran SV, Ikegami T, Front Cell Infect Microbiol 2012 2 131 23112960
13. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins KA, Edwards NJ, Douglas AD, Anagnostou NA, et al. Mol Ther 2012 20 2355 2368 10.1038/mt.2012.223 23089736
14. Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects. Howles S, Guimaraes-Walker A, Yang H, Hancock G, di Gleria K, Tarragona-Fiol T, Hayes P, Gilmour J, Bridgeman A, Hanke T, et al. Vaccine 2010 28 7306 7312 10.1016/j.vaccine.2010.08.077 20816902
15. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, Kadira B, Mauff K, Moyo S, Brittain N, Lawrie A, et al. Am J Respir Crit Care Med 2012 185 769 778 10.1164/rccm.201108-1548OC 22281831
16. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, et al. Sci Transl Med 2012 4 115 ra111
17. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP + M1, in humans. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, et al. Clin Infect Dis 2012 55 19 25 10.1093/cid/cis327 22441650
18. Use of adenoviral vectors as veterinary vaccines. Ferreira TB, Alves PM, Aunins JG, Carrondo MJ, Gene Ther 2005 12 Suppl 1 73 S83 16231058
19. A novel recombinant Peste des petits ruminants-canine adenovirus vaccine elicits long-lasting neutralizing antibody response against PPR in goats. Qin J, Huang H, Ruan Y, Hou X, Yang S, Wang C, Huang G, Wang T, Feng N, Gao Y, Xia X, PLoS One 2012 7 37170 10.1371/journal.pone.0037170 22623990
20. Canine recombinant adenovirus vector induces an immunogenicity-related gene expression profile in skin-migrated CD11b(+) -type DCs. Contreras V, Urien C, Jouneau L, Bourge M, Bouet-Cararo C, Bonneau M, Zientara S, Klonjkowski B, Schwartz-Cornil I, PLoS One 2012 7 52513 10.1371/journal.pone.0052513 23300693
21. Goats primed with Mycobacterium bovis BCG and boosted with a recombinant adenovirus expressing Ag85A show enhanced protection against tuberculosis. Perez de Val B, Villarreal-Ramos B, Nofrarias M, Lopez-Soria S, Romera N, Singh M, Abad FX, Xing Z, Vordermeier HM, Domingo M, Clin Vaccine Immunol 2012 19 1339 1347 10.1128/CVI.00275-12 22761299
22. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, Thacker T, Gilbert SC, McShane H, Hill AV, Xing Z, Hewinson RG, Infect Immun 2009 77 3364 3373 10.1128/IAI.00287-09 19487476
23. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins. Sanz-Parra A, Vazquez B, Sobrino F, Cox SJ, Ley V, Salt JS, J Gen Virol 1999 80 Pt 3 671 679 10092007 (Pubitemid 29101222)
24. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Grubman MJ, Biologicals 2005 33 227 234 10.1016/j.biologicals.2005.08.009 16289996 (Pubitemid 41743812)
25. Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. Torres JM, Alonso C, Ortega A, Mittal S, Graham F, Enjuanes L, J Virol 1996 70 3770 3780 8648712 (Pubitemid 26157356)
26. Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against Taenia ovis infection in sheep. Rothel JS, Boyle DB, Both GW, Pye AD, Waterkeyn JG, Wood PR, Lightowlers MW, Parasite Immunol 1997 19 221 227 10.1046/j.1365-3024.1997.d01-200.x 9194099 (Pubitemid 27242524)
27. Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1. Zakhartchouk AN, Pyne C, Mutwiri GK, Papp Z, Baca-Estrada ME, Griebel P, Babiuk LA, Tikoo SK, J Gen Virol 1999 80 Pt 5 1263 1269 10355773 (Pubitemid 29213814)
28. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AV, Cottingham MG, PLoS One 2012 7 40385 10.1371/journal.pone.0040385 22808149
29. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, et al. Sci Transl Med 2012 4 115 ra112
30. Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. Roy S, Vandenberghe LH, Kryazhimskiy S, Grant R, Calcedo R, Yuan X, Keough M, Sandhu A, Wang Q, Medina-Jaszek CA, et al. PLoS Pathog 2009 5 1000503 10.1371/journal.ppat.1000503 19578438
31. A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity. Holman DH, Penn-Nicholson A, Wang D, Woraratanadharm J, Harr MK, Luo M, Maher EM, Holbrook MR, Dong JY, Clin Vaccine Immunol 2009 16 1624 1632 10.1128/CVI.00182-09 19776190
32. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nostbakken JK, et al. Vaccine 2011 29 8049 8059 10.1016/j.vaccine.2011.08.042 21864624
33. The history of MF59((R)) adjuvant: a phoenix that arose from the ashes. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD, Expert Rev Vaccines 2013 12 13 30 10.1586/erv.12.140 23256736
34. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ, Influenza Other Respir Viruses 2011 5 426 437 10.1111/j.1750-2659.2011.00256.x 21668670
35. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. Goff PH, Eggink D, Seibert CW, Hai R, Martinez-Gil L, Krammer F, Palese P, PLoS One 2013 8 79194 10.1371/journal.pone. 0079194 24223176
36. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Madhun AS, Haaheim LR, Nilsen MV, Cox RJ, Vaccine 2009 27 7367 7376 10.1016/j.vaccine.2009.09.044 19781678
37. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Draper SJ, Goodman AL, Biswas S, Forbes EK, Moore AC, Gilbert SC, Hill AV, Cell Host Microbe 2009 5 95 105 10.1016/j.chom.2008.12.004 19154991
38. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A, Expert Rev Vaccines 2013 12 379 393 10.1586/erv.13.15 23560919
39. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Dudareva M, Andrews L, Gilbert SC, Bejon P, Marsh K, Mwacharo J, Kai O, Nicosia A, Hill AV, Vaccine 2009 27 3501 3504 10.1016/j.vaccine.2009.03.080 19464527
40. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al. Lancet 2008 372 1881 1893 10.1016/S0140-6736(08)61591-3 19012954
41. Novel approaches to foot-and-mouth disease vaccine development. Ludi A, Rodriguez L, Dev Biol (Basel) 2013 135 107 116 23689888
42. Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Bouloy M, Flick R, Antiviral Res 2009 84 101 118 10.1016/j.antiviral.2009.08.002 19682499
43. Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses. Dodd KA, McElroy AK, Jones ME, Nichol ST, Spiropoulou CF, J Virol 2013 87 6161 6171 10.1128/JVI.00337-13 23536675
44. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8 + -T cell activation and protects immune-competent mice against a lethal RVFV infection. Lopez-Gil E, Lorenzo G, Hevia E, Borrego B, Eiden M, Groschup M, Gilbert SC, Brun A, PLoS Negl Trop Dis 2013 7 2309 10.1371/journal.pntd.0002309 23875044
45. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. Caplen H, Peters CJ, Bishop DH, J Gen Virol 1985 66 Pt 10 2271 2277 4045430 (Pubitemid 15250309)
46. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Graham FL, Smiley J, Russell WC, Nairn R, J Gen Virol 1977 36 59 74 10.1099/0022-1317-36-1-59 886304
47. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. Biswas S, Dicks MD, Long CA, Remarque EJ, Siani L, Colloca S, Cottingham MG, Holder AA, Gilbert SC, Hill AV, Draper SJ, PLoS One 2011 6 20977 10.1371/journal.pone. 0020977 21698193
48. Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. Romero P, Maryanski JL, Cordey AS, Corradin G, Nussenzweig RS, Zavala F, Immunol Lett 1990 25 27 31 10.1016/0165-2478(90)90086- 6 1704348 (Pubitemid 20260840)
49. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Reyes-Sandoval A, Rollier CS, Milicic A, Bauza K, Cottingham MG, Tang CK, Dicks MD, Wang D, Longley RJ, Wyllie DH, Hill AV, Mol Ther 2012 20 1633 1647 10.1038/mt.2012.25 22354374
50. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). Cottingham MG, Andersen RF, Spencer AJ, Saurya S, Furze J, Hill AV, Gilbert SC, PLoS One 2008 3 1638 10.1371/journal.pone.0001638 18286194 (Pubitemid 351865468)
51. The pathogenesis of Rift Valley fever virus in the mouse model. Smith DR, Steele KE, Shamblin J, Honko A, Johnson J, Reed C, Kennedy M, Chapman JL, Hensley LE, Virology 2010 407 256 267 10.1016/j.virol.2010.08.016 20850165